Dr Adler is a Consultant Physician at Addenbrooke's Hospital, Cambridge, and Chair of Technology Appraisal Committee B at the National Institute for Health and Care Excellence (NICE). She trained in economics, medicine and epidemiology in the US, and in pharmovigilance and pharmacoepidemiology in the UK.
With NICE, she chaired the Clinical Guidelines for Newer Agents for Type 2 Diabetes, the Quality Standard for Diabetes, and Cancer Drug Fund decisions. With NICE International, she participated in projects setting priorities under universal health coverage with the Gates Foundation, the World Bank, and the Organisation for Economic Co-operation and Development (OECD).
Dr Adler was the Clinical Epidemiologist for the UK Prospective Diabetes Study (UKPDS). She is on the steering committee for ASCEND (Clinical Trials Service Unit, Oxford), was on the executive committee for TECOS (Diabetes Trials Unit, Oxford), and collaborates on the adaptively-designed STAMPEDE (MRC Clinical Trials Unit (London). She serves on the UK Commission on Human Medicines Expert Advisory Group on Cardiovascular, Diabetes, Renal, Respiratory and Allergy. Dr. Adler chaired the Expert Group on the Safety of Insulin for Britain’s Medicines and Health products Regulatory Agency.